Chilean Chia Supplier Benexia Secures Supply Chain, Sees Demand Rise Amid Pandemic
Benexia, a Chilean chia producer, maintained production and supply continuity during the pandemic due to strategic inventory planning and favourable local regulations, leading to increased demand for its omega-3 rich products.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Santiago, Chile — 29 May 2020
Chilean chia seed producer Benexia leveraged prior planning and favourable local legislation to ensure supply chain continuity and increased demand for its omega-3 products during the COVID-19 pandemic. The company, headquartered in Chile with crop cultivation in Argentina and Bolivia, maintained normal industrial operations, citing Chilean food industry protections as crucial for production plant functionality. This proactive stance allowed Benexia to secure essential genetics for planting season early in the pandemic, ensuring consistent raw material supply when competitors faced disruptions, according to CEO Sandra Gillot.
Benexia, which also manufactures finished goods under the SOW (Seeds of Wellness) brand including chia pastas, oils, and supplements, observed a significant shift in consumer purchasing habits. Demand for products rich in alpha-linolenic acid (ALA), an omega-3 fatty acid, surged due to perceived links with inflammation support. Gillot noted that while ALA doesn't directly impact immune response to pathogens, its role in mitigating inflammatory responses resonated with consumers seeking health advantages during the crisis. The company's SOW chia pastas and oils experienced substantial sales growth through both brick-and-mortar retail and online channels as consumers prioritised health-supporting food choices.
Strategic inventory management proved critical for Benexia. Unlike many brands struggling with stock-outs amidst unpredictable demand spikes, Benexia's robust inventory levels allowed them to meet increased retailer and consumer requirements. This created market openings for smaller brands prepared to capitalise on the inability of larger, less agile players to maintain consistent supply. Retailers, facing heightened consumer demand, opted to increase stock levels on readily available, health-positioned items.
What this means for United Kingdom
UK brand owners must re-evaluate their inventory strategies, holding 90-120 days of critical ingredient stock to mitigate future supply chain shocks and capitalise on market opportunities. Reformulation windows for new product development should prioritise ingredients with demonstrable anti-inflammatory or immune-modulating properties to align with evolving consumer health priorities. Brands should assess current regulatory frameworks for 'immune support' claims, ensuring compliance with EFSA guidelines while developing robust marketing narratives for products like ALA omega-3s. Competitive positioning requires agile sourcing and direct-to-consumer channel optimisation to capture increased demand for functional foods and supplements.
Benexia’s experience underscores the commercial value of vertical integration and supply chain resilience. Manufacturers with control over their raw material sourcing and robust contingency plans are better positioned to weather macroeconomic disruptions. The sustained consumer focus on immune and inflammatory support will continue to drive demand for specific functional ingredients, demanding clear, compliant messaging from brand owners.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.